Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02657993 · ClinicalTrials.gov registry record · NA

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

A NA study of Breast Neoplasms and Musculoskeletal Pain, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
191
Enrollment target
1
Study location

NCT02657993: Completed NA study of Breast Neoplasms and Musculoskeletal Pain, sponsored by Icahn School of Medicine at Mount Sinai.

NCT02657993 is a NA study of Breast Neoplasms and Musculoskeletal Pain that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 191 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02657993, a NA study of Breast Neoplasms and Musculoskeletal Pain, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
191 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether hypnosis is efficacious in reducing musculoskeletal pain in breast cancer survivors taking aromatase inhibitors, and by doing so, whether hypnosis can help survivors to be more adherent to their medication regimen.

Primary Outcome

The Brief Pain Inventory-Short Form (BPI-SF) is a self-report questionnaire assessing pain.

Interventions

  • BEHAVIORAL Attention Control
  • BEHAVIORAL Hypnosis

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 191 participants
Start Date 2016-03
Est. Completion 2021-03-18
Phase NA

What the finished NCT02657993 record still lists

NCT02657993 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (66% lower).

The record links to 2 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Attention Control is the first listed.

NCT02657993 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02657993 about?

NCT02657993 is a clinical study titled "Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence". The purpose of this study is to determine whether hypnosis is efficacious in reducing musculoskeletal pain in breast cancer survivors taking aromatase inhibitors, and by doing so, whether hypnosis can help survivors to be more adherent to their medication regimen.

What is the current status of trial NCT02657993?

This trial is currently completed. It is a NA study. The enrollment target is 191 participants. The study started on 2016-03. Estimated completion is 2021-03-18.

What conditions does trial NCT02657993 study?

This clinical trial studies the following conditions: Breast Neoplasms, Musculoskeletal Pain.

What interventions are being tested in trial NCT02657993?

The interventions under investigation include: Attention Control (BEHAVIORAL), Hypnosis (BEHAVIORAL).

Who is sponsoring clinical trial NCT02657993?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02657993 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02657993's enrollment target sits among peer trials

191 41st of 97 higher than 57 of 97 other Breast Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04621435 · 191 participants · Phase 1

    Imaging of Solid Tumors Using FAP-2286

  • NCT06810544 · 191 participants · Phase 1

    Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • NCT01492972 · 192 participants · Phase 3

    Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  • NCT01973881 · 192 participants

    Quantitative MRI for Myelofibrosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02657993, the US trial registry maintained by the National Library of Medicine. NCT02657993 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.